Acrivon Therapeutics (ACRV) News Today $1.18 +0.03 (+2.17%) As of 12:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy RatingMay 21 at 3:15 PM | tipranks.comHC Wainwright Issues Optimistic Estimate for ACRV EarningsMay 20 at 2:21 AM | americanbankingnews.comFY2025 EPS Estimate for Acrivon Therapeutics Cut by AnalystMay 19 at 3:07 AM | americanbankingnews.comAcrivon Therapeutics' (ACRV) Hold Rating Reiterated at Jones TradingMay 18, 2025 | americanbankingnews.comCantor Fitzgerald maintains Overweight on Acrivon Therapeutics stockMay 17, 2025 | uk.investing.comOppenheimer Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)May 17, 2025 | theglobeandmail.comPiper Sandler Reaffirms Their Buy Rating on Acrivon Therapeutics, Inc. (ACRV)May 17, 2025 | theglobeandmail.comJones Trading Downgrades Acrivon Therapeutics (ACRV)May 17, 2025 | msn.comAcrivon Therapeutics downgraded to Hold from Buy at JonesResearchMay 17, 2025 | finance.yahoo.comOppenheimer Issues Pessimistic Forecast for Acrivon Therapeutics (NASDAQ:ACRV) Stock PriceMay 17, 2025 | americanbankingnews.comAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 16, 2025 | finanznachrichten.deAcrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy RatingMay 15, 2025 | tipranks.comAcrivon Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 14, 2025 | globenewswire.comInsider Selling: Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Sells 437,881 Shares of StockMay 2, 2025 | insidertrades.comMajor Shareholder Sells Massive Stake in Acrivon Therapeutics!May 1, 2025 | tipranks.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Sells $335,841.48 in StockApril 30, 2025 | insidertrades.comMajor Shareholder Sells Millions in Acrivon Therapeutics Stock!April 29, 2025 | tipranks.comMarshall Wace LLP Sells 212,065 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV)Marshall Wace LLP trimmed its position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 26.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 597,794 shares of the company's stock after selling 212,065April 28, 2025 | marketbeat.comAcrivon Therapeutics to present data from analyses of ACR-2316 at AACRApril 26, 2025 | markets.businessinsider.comAcrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025April 25, 2025 | globenewswire.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in MarchAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 887,100 shares, a growth of 21.4% from the March 15th total of 730,600 shares. Based on an average daily volume of 120,400 shares, the days-to-cover ratio is currently 7.4 days. Currently, 4.1% of the company's shares are sold short.April 21, 2025 | marketbeat.comAcrivon appoints new chief medical officer to advance cancer trialsApril 10, 2025 | uk.investing.comAcrivon appoints Mansoor Raza Mirza as Chief Medical OfficerApril 9, 2025 | markets.businessinsider.comAcrivon Therapeutics Reports Progress in Cancer Drug DevelopmentApril 8, 2025 | tipranks.comAcrivon Therapeutics Appoints New Chief Medical OfficerApril 7, 2025 | tipranks.comAcrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical OfficerApril 7, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for ACRV Q1 Earnings?Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Acrivon Therapeutics in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst E. Bodnar anticipates that the companyMarch 29, 2025 | marketbeat.comAcrivon Therapeutics price target lowered to $10 from $18 at OppenheimerMarch 29, 2025 | markets.businessinsider.comAcrivon Therapeutics (NASDAQ:ACRV) Releases Earnings ResultsAcrivon Therapeutics (NASDAQ:ACRV - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.06.March 28, 2025 | marketbeat.comEquities Analysts Set Expectations for ACRV FY2029 EarningsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings estimates for Acrivon Therapeutics in a research report issued on Wednesday, March 26th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.2March 28, 2025 | marketbeat.comAcrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 27, 2025 | globenewswire.comCantor Fitzgerald Reiterates "Overweight" Rating for Acrivon Therapeutics (NASDAQ:ACRV)Cantor Fitzgerald reissued an "overweight" rating on shares of Acrivon Therapeutics in a research note on Wednesday.March 27, 2025 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $19.00 by Analysts at HC WainwrightHC Wainwright cut their target price on Acrivon Therapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a report on Wednesday.March 27, 2025 | marketbeat.comAcrivon Therapeutics: Promising Oncology Advancements and Strategic Positioning Justify Buy RatingMarch 24, 2025 | tipranks.comAcrivon Therapeutics (ACRV) to Release Quarterly Earnings on ThursdayAcrivon Therapeutics (NASDAQ:ACRV) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comAcrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program UpdatesMarch 19, 2025 | globenewswire.comAcrivon Therapeutics appoints new CFO as predecessor steps downMarch 16, 2025 | investing.comShort Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 33.7%Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 748,700 shares, a drop of 33.7% from the February 13th total of 1,130,000 shares. Currently, 3.5% of the shares of the company are sold short. Based on an average daily volume of 56,200 shares, the short-interest ratio is currently 13.3 days.March 15, 2025 | marketbeat.comAcrivon Therapeutics Appoints New Chief Financial OfficerMarch 14, 2025 | tipranks.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have received a consensus rating of "Buy" from the eight brokerages that are presently covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average 12 month target price among bMarch 11, 2025 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest UpdateAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,100,000 shares, a drop of 6.0% from the January 15th total of 1,170,000 shares. Based on an average daily volume of 60,300 shares, the days-to-cover ratio is presently 18.2 days. Currently, 5.0% of the company's stock are sold short.February 18, 2025 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Buy" by AnalystsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been assigned a consensus rating of "Buy" from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objFebruary 14, 2025 | marketbeat.comAcrivon Therapeutics announces FDA granted BDD for ACR-368February 6, 2025 | markets.businessinsider.comAcrivon Therapeutics Stock Rises 14% On FDA Recognition For ACR-368 OncoSignature AssayFebruary 5, 2025 | markets.businessinsider.comAcrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough StatusFebruary 5, 2025 | msn.comAcrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer IdentificationFebruary 5, 2025 | marketwatch.comACR-368 OncoSignature assay gains FDA breakthrough statusFebruary 5, 2025 | msn.comAcrivon Therapeutics:FDA Grants Breakthrough Device Designation For ACR-368 OncoSignature AssayFebruary 5, 2025 | markets.businessinsider.comAcrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial CancerFebruary 5, 2025 | finance.yahoo.comBrokers Offer Predictions for ACRV FY2024 EarningsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for Acrivon Therapeutics in a report released on Monday, February 3rd. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($2.42) per share fFebruary 5, 2025 | marketbeat.com Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Media Mentions By Week ACRV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼0.130.65▲Average Medical News Sentiment ACRV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼192▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Korro Bio News Today Aclaris Therapeutics News Today Fate Therapeutics News Today Eupraxia Pharmaceuticals News Today Inhibikase Therapeutics News Today Greenwich LifeSciences News Today Protalix BioTherapeutics News Today Protara Therapeutics News Today Silence Therapeutics News Today FitLife Brands News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRV) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRV Stock Free ACRV Stock Alerts